US 11,890,303 B2
Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse
Matthias Stephan, Seattle, WA (US)
Assigned to Fred Hutchinson Cancer Center, Seattle, WA (US)
Filed by Fred Hutchinson Cancer Center, Seattle, WA (US)
Filed on Sep. 30, 2020, as Appl. No. 17/039,671.
Application 17/039,671 is a continuation of application No. 16/156,996, filed on Oct. 10, 2018, granted, now 10,806,756, issued on Oct. 20, 2020.
Application 16/156,996 is a continuation of application No. 16/155,801, filed on Oct. 9, 2018, granted, now 10,702,551, issued on Jul. 7, 2020.
Application 16/155,801 is a continuation of application No. 14/760,695, abandoned, previously published as PCT/US2014/011526, filed on Jan. 14, 2014.
Claims priority of provisional application 61/900,922, filed on Nov. 6, 2013.
Claims priority of provisional application 61/752,423, filed on Jan. 14, 2013.
Prior Publication US 2021/0015863 A1, Jan. 21, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/17 (2015.01); A61K 9/00 (2006.01); A61K 9/14 (2006.01); A61K 39/44 (2006.01); C07K 16/28 (2006.01); A01K 67/027 (2006.01); C12N 5/09 (2010.01); A61K 45/06 (2006.01)
CPC A61K 35/17 (2013.01) [A01K 67/0271 (2013.01); A61K 9/0024 (2013.01); A61K 9/146 (2013.01); A61K 39/44 (2013.01); A61K 45/06 (2013.01); C07K 16/2809 (2013.01); C07K 16/2818 (2013.01); C07K 16/2878 (2013.01); C12N 5/0694 (2013.01); A01K 2207/12 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0331 (2013.01); C12N 2510/00 (2013.01); C12N 2533/54 (2013.01); C12N 2533/74 (2013.01)] 19 Claims
 
1. An ex vivo implantable composition comprising (i) a porous scaffold comprising pores; (ii) tumor reactive lymphocytes within the pores; and (iii) at least one antibody selected from an anti-CD3 antibody, an anti-CD28 antibody, and an anti-CD137 antibody.